Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.38 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6496755 | 0.90 | PDE3B (0.44) | PDE3BPDE3AP2RY12PLA2G2ABRD4 | |
| SCHEMBL6489517 | 0.89 | PDE3B (0.43) | PDE3BPDE3AP2RY12PLA2G2ABRD4 | |
| SCHEMBL6487030 | 0.87 | PDE3B (0.42) | PDE3BPDE3AP2RY12PLA2G2ABRD4 | |
| SCHEMBL6488241 | 0.87 | MCL1 (0.43) | PDE3BPDE3AP2RY12PLA2G2ABRD4 | |
| SCHEMBL6499705 | 0.85 | PDK2 (0.40) | PDE3BPDE3AP2RY12PLA2G2ABRD4 | |
| SCHEMBL6487942 | 0.82 | MCL1 (0.42) | PDE3BPDE3AP2RY12PLA2G2ABRD4 | |
| SCHEMBL6488122 | 0.82 | MCL1 (0.46) | PDE3BPDE3AP2RY12PLA2G2AMCL1 | |
| SCHEMBL6491512 | 0.81 | MCL1 (0.41) | PDE3BPDE3AP2RY12PLA2G2ABRD4 | |
| SCHEMBL6497299 | 0.81 | PDE3B (0.40) | PDE3BPDE3AP2RY12PLA2G2AMCL1 | |
| SCHEMBL6502915 | 0.81 | SMN1; SMN2 (0.44) | PDE3BPDE3AP2RY12PLA2G2ABRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | PDE3B 411/4885PDE3A 733/4885P2RY12 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.